Challenge and rechallenge: Drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis

被引:5
作者
Castelli, EE
Culley, CM
Fink, MR
机构
[1] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA
来源
PHARMACOTHERAPY | 2005年 / 25卷 / 08期
关键词
drotrecogin alfa (activated); anticoagulation; sepsis; partial thromboplastin time;
D O I
10.1592/phco.2005.25.8.1147
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An 81-year-old woman with ischemic bowel underwent laparotomy with small-bowel resection and developed septic shock. She required broad-spectrum antibiotics, norepinephrine, and mechanical ventilation. The patient received drotrecogin alfa (activated) 24 mu g/kg/hour for a total of 67.5 hours. Coagulation parameters were monitored during her therapy. Significant increases in activated partial thromboplastin time (aPTT) during infusion led to two temporary discontinuations of the drug. Coagulation parameters decreased when the drug was held and increased with each rechallenge. The patient survived the episode and was discharged on postoperative day 27. Medical records of 26 other patients who received drotrecogin alfa (activated) at our institution from November 2001-August 2003 were reviewed retrospectively for coagulation parameters and bleeding rate. Of the 26 patients, nine (35%) were treatment compliant (> 90% of the 96-hr course). Coagulopathy and bleeding resulted in early discontinuation in four (15%) and six (23%) patients, respectively An increase in aPTT from baseline to during infusion of drotrecogin alfa (activated) was noted in 14 patients with complete data (p=0.56). A decrease in median platelet count from baseline to during infusion was noted in the six patients who bled during therapy (p=0.01). Two of these patients had platelet counts less than 30 x 10(3)/mm(3) during administration. Drotrecogin alfa (activated) should be considered an anticoagulant. In postmarketing reports, clinically significant bleeding occurred more frequently than was noted in a large, randomized, multicenter trial. Patients receiving drotrecogin alfa (activated) should be closely monitored for prolongation of coagulation parameters. Temporary discontinuation of the drug should be considered when international normalized ratio is greater than 3.0, platelet count is less than 15 x 10(3)/mm(3), and aPTT is greater than 100 seconds.
引用
收藏
页码:1147 / 1150
页数:4
相关论文
共 17 条
  • [1] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [2] Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis
    Bernard, GR
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (01) : S85 - S93
  • [3] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [4] Castelli EE, 2003, CRIT CARE MED, V31, pA122
  • [5] Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis
    de Pont, ACJM
    Bouman, CSC
    de Jonge, E
    Vroom, MB
    Büller, HR
    Levi, M
    [J]. INTENSIVE CARE MEDICINE, 2003, 29 (07) : 1205 - 1205
  • [6] Inflammation and coagulation: Implications for the septic patient
    Dellinger, RP
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (10) : 1259 - 1265
  • [7] Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis
    Dhainaut, JF
    Yan, SB
    Cariou, A
    Mira, JP
    [J]. CRITICAL CARE MEDICINE, 2002, 30 (05) : S318 - S324
  • [8] Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis
    Dhainaut, JFO
    Yan, SB
    Margolis, BD
    Lorente, JA
    Russell, JA
    Freebairn, RC
    Spapen, HD
    Riess, H
    Basson, B
    Johnson, G
    Kinasewitz, GT
    [J]. THROMBOSIS AND HAEMOSTASIS, 2003, 90 (04) : 642 - 653
  • [9] *EL LILL COMP, 2003, XIGR DROTR ALF
  • [10] EVANS HL, 2003, CRIT CARE S2, V7, P22